BC Innovations | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

Lykera joins a growing wave of companies targeting the tumor stroma, but it is taking a different approach with a portfolio of first-in-class mAbs against S100 proteins implicated in driving metastases. Its lead programs are...
BC Week In Review | Aug 10, 2018
Clinical News

Active, Teva's laquinimod misses in Phase II for HD

Active Biotech AB (SSE:ACTI) said once-daily 1 mg oral laquinimod missed the primary endpoint of improving the Unified Huntington's Disease Rating Scale - Total Motor Score (UHDRS-TMS) from baseline to 12 months vs. placebo in the...
BioCentury | Jan 9, 2018
Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
BC Week In Review | Dec 8, 2017
Clinical News

Active, Teva's laquinimod misses in Phase II for PPMS

Active Biotech AB (SSE:ACTI) said once-daily 0.6 mg oral laquinimod (SAIK-MS) missed the primary endpoint of reducing brain atrophy on MRI as measured by percent brain volume change from baseline to week 48 compared to...
BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

After spending the last six years plugging revenue holes via licensing and M&A, Ipsen Group is once again on track to meet the 2020 financial targets it set at the beginning of the decade. But...
BioCentury | Jul 7, 2017
Finance

Onward and upward

The top three market cap tiers continued to outperform smaller caps in 2Q17, led by companies valued between $1 billion and $9.9 billion. Companies valued below $1 billion failed to carry over their momentum from...
BC Extra | Jun 21, 2017
Company News

Management tracks

Biogen Inc. (NASDAQ:BIIB) named Ginger Gregory EVP and chief human resources officer, effective July 17. She was chief human resources officer at Shire plc (LSE:SHP; NASDAQ:SHPG). Neurodegenerative, inflammation and cancer company Active Biotech AB (SSE:ACTI)...
BC Innovations | Jun 7, 2017
Distillery Therapeutics

Cardiovascular; hematology

INDICATION: Atherosclerosis; hematology Patient sample and mouse studies suggest inhibiting S100A9 could help treat diabetes-related atherosclerosis and thrombocytosis. In plasma samples from Type II diabetes patients, levels of S100A9 were higher than in samples from...
BC Week In Review | May 12, 2017
Clinical News

Teva's laquinimod fails Phase III RRMS trial

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) and partner Active Biotech AB (SSE:ACTI) said once-daily 0.6 mg laquinimod (SAIK-MS) missed the primary endpoint in the Phase III CONCERTO trial to treat relapsing-remitting multiple sclerosis (RRMS)....
BC Extra | May 5, 2017
Clinical News

Teva's laquinimod fails Phase III RRMS study

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and partner Active Biotech AB (SSE:ACTI) said laquinimod (SAIK-MS) missed the primary endpoint in the Phase III CONCERTO trial to treat relapsing-remitting multiple sclerosis. Teva said it has "no current...
Items per page:
1 - 10 of 332
BC Innovations | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

Lykera joins a growing wave of companies targeting the tumor stroma, but it is taking a different approach with a portfolio of first-in-class mAbs against S100 proteins implicated in driving metastases. Its lead programs are...
BC Week In Review | Aug 10, 2018
Clinical News

Active, Teva's laquinimod misses in Phase II for HD

Active Biotech AB (SSE:ACTI) said once-daily 1 mg oral laquinimod missed the primary endpoint of improving the Unified Huntington's Disease Rating Scale - Total Motor Score (UHDRS-TMS) from baseline to 12 months vs. placebo in the...
BioCentury | Jan 9, 2018
Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
BC Week In Review | Dec 8, 2017
Clinical News

Active, Teva's laquinimod misses in Phase II for PPMS

Active Biotech AB (SSE:ACTI) said once-daily 0.6 mg oral laquinimod (SAIK-MS) missed the primary endpoint of reducing brain atrophy on MRI as measured by percent brain volume change from baseline to week 48 compared to...
BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

After spending the last six years plugging revenue holes via licensing and M&A, Ipsen Group is once again on track to meet the 2020 financial targets it set at the beginning of the decade. But...
BioCentury | Jul 7, 2017
Finance

Onward and upward

The top three market cap tiers continued to outperform smaller caps in 2Q17, led by companies valued between $1 billion and $9.9 billion. Companies valued below $1 billion failed to carry over their momentum from...
BC Extra | Jun 21, 2017
Company News

Management tracks

Biogen Inc. (NASDAQ:BIIB) named Ginger Gregory EVP and chief human resources officer, effective July 17. She was chief human resources officer at Shire plc (LSE:SHP; NASDAQ:SHPG). Neurodegenerative, inflammation and cancer company Active Biotech AB (SSE:ACTI)...
BC Innovations | Jun 7, 2017
Distillery Therapeutics

Cardiovascular; hematology

INDICATION: Atherosclerosis; hematology Patient sample and mouse studies suggest inhibiting S100A9 could help treat diabetes-related atherosclerosis and thrombocytosis. In plasma samples from Type II diabetes patients, levels of S100A9 were higher than in samples from...
BC Week In Review | May 12, 2017
Clinical News

Teva's laquinimod fails Phase III RRMS trial

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) and partner Active Biotech AB (SSE:ACTI) said once-daily 0.6 mg laquinimod (SAIK-MS) missed the primary endpoint in the Phase III CONCERTO trial to treat relapsing-remitting multiple sclerosis (RRMS)....
BC Extra | May 5, 2017
Clinical News

Teva's laquinimod fails Phase III RRMS study

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and partner Active Biotech AB (SSE:ACTI) said laquinimod (SAIK-MS) missed the primary endpoint in the Phase III CONCERTO trial to treat relapsing-remitting multiple sclerosis. Teva said it has "no current...
Items per page:
1 - 10 of 332